Biotech Growth Trust plc (The) (BIOG) Ordinary 25p
- Add to watchlist
- Create an alert
- This stock can be held in a
999.00p
1,010.54p
1,048.00p
1,076.47
990.00p
983.00p
715.00p
-8.03%
10.00p (1.00%) Previous:
10.00p
17,611
n/a
GBX
Price
-
Net Asset Value (NAV)
Performance
1 week 1W | 2.48% | 1 year 1Y | 18.01% |
---|---|---|---|
1 month 1M | 3.69% | 2 years 2Y | 19.3% |
3 months 3M | 2.13% | 3 years 3Y | 25.42% |
6 months 6M | 29.17% | 5 years 5Y | 36.91% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | NASDAQ Biotechnology TR GBP |
---|---|
Annual management charge: | n/a |
Performance fee: | Yes |
Ongoing charge: | 1.30% |
Dividend yield: | n/a |
Dividend frequency: | None |
Total assets: | £392m |
Gross gearing: | 9% |
Market capitalisation:Market cap.: | £330m |
Shares in issue: | 33.37 million |
Legal structure | Closed Ended Investment Company |
Domicile: | United Kingdom |
ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | 1,076.47 |
---|---|
Latest actual NAV: | 1,076.64 |
Latest actual NAV date: | 16 May 2024 |
Premium/Discount: | -8.03% |
12m average Premium/Discount: | -7.41% |
NAV frequency: | Daily |
Security | Weight |
---|---|
Amgen Inc | 9.30% |
Biogen Inc | 7.86% |
Regeneron Pharmaceuticals Inc | 4.99% |
Vaxcyte Inc Ordinary Shares | 4.68% |
Sarepta Therapeutics Inc | 4.49% |
Ionis Pharmaceuticals Inc | 4.32% |
Argen X SE EUR0.10 | 3.85% |
Quantumpharm Inc (Xtalpi) - Pfd | 3.31% |
Scholar Rock Holding Corp | 3.27% |
Apellis Pharmaceuticals Inc | 2.97% |
Sector | Weight |
---|---|
Healthcare | 100.55% |
Country | Weight |
---|---|
United States | 91.49% |
China | 5.73% |
Germany | 1.72% |
Canada | 1.60% |
Key Dates
Launch date: | 23 June 1997 |
---|---|
Financial year end: | March |
Next AGM: | July 2024 |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.